Higher than expected staff losses at the European Medicines Agency due to the relocations to Amsterdam are posing challenges to implement new EU legislation. While the planned move to a permanent HQ in the Dutch capital has led to a decrease in staff, the agency is having to further prioritize its business activities.
Author: Informa Pharma Intelligence
Published: 02 September 2019
Number of pages:3
The European Medicine Agency’s Brexit-related move to Amsterdam from its London office in March had already led to staff losses. Now the agency says they have seen further decline in the past few months and that it will be difficult to carry out its work program for the final quarter of 2019 particularly in view of the need to implement new legislation for veterinary medicines and medical devices and additional work that will create. Pink Sheet shares headcount totals from the beginning until now and details about the agency’s interim space until it moves into its permanent home.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.